Repatha pushtronex The Pushtronex system is an on-body infusor with a prefilled cartridge intended for once-monthly administration. Amgen announced that the Food and Drug Administration (FDA) has ...

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...

Amgen has won FDA approval for a new device that allows for monthly dosing of its cholesterol-busting drug Repatha. Is it a game-changing innovation in its fight against Regeneron Pharmaceuticals and ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...

Amgen Inc.AMGN announced that the FDA has approved a new, monthly single-dose administration option for its PCSK9 inhibitor, Repatha. The Repatha Pushtronex system, an on-body infusor with a prefilled ...

Repatha reduced the risk of heart attack by 27%, the risk of stroke by 21% and the risk of coronary revascularization by 22%. Amgen announced that the Food and Drug Administration (FDA) has approved ...

Repatha may help reduce the risk of heart attack, stroke, and heart surgery for adults with heart disease. It might also lower low-density lipoprotein (LDL) cholesterol in adults and children with ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

Biotech giant Amgen (NASDAQ: AMGN) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly, ...